Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Net Margin: 2019-2025

Historic Net Margin for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -1,162.38%.

  • Beam Therapeutics' Net Margin fell 48492.00% to -1,162.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -744.41%, marking a year-over-year decrease of 70334.00%. This contributed to the annual value of -593.13% for FY2024, which is 55804.00% down from last year.
  • Per Beam Therapeutics' latest filing, its Net Margin stood at -1,162.38% for Q3 2025, which was up 3.80% from -1,208.26% recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Net Margin registered a high of 45.16% during Q4 2023, and its lowest value of -3,359,333.33% during Q1 2021.
  • Moreover, its 3-year median value for Net Margin was -677.47% (2024), whereas its average is -749.10%.
  • As far as peak fluctuations go, Beam Therapeutics' Net Margin slumped by 283,041,667bps in 2021, and later surged by 335,851,248bps in 2022.
  • Over the past 5 years, Beam Therapeutics' Net Margin (Quarterly) stood at -126.71% in 2021, then crashed by 6,469bps to -191.39% in 2022, then surged by 23,655bps to 45.16% in 2023, then plummeted by 34,567bps to -300.51% in 2024, then slumped by 48,492bps to -1,162.38% in 2025.
  • Its Net Margin stands at -1,162.38% for Q3 2025, versus -1,208.26% for Q2 2025 and -1,462.78% for Q1 2025.